BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36150551)

  • 21. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.
    Donehower LA; Creighton CJ; Schultz N; Shinbrot E; Chang K; Gunaratne PH; Muzny D; Sander C; Hamilton SR; Gibbs RA; Wheeler D
    J Pathol; 2013 Jan; 229(1):99-110. PubMed ID: 22899370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct WNT/β-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum.
    Murakami T; Mitomi H; Saito T; Takahashi M; Sakamoto N; Fukui N; Yao T; Watanabe S
    Mod Pathol; 2015 Jan; 28(1):146-58. PubMed ID: 24925057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.
    Kim KM; Lee EJ; Ha S; Kang SY; Jang KT; Park CK; Kim JY; Kim YH; Chang DK; Odze RD
    Am J Surg Pathol; 2011 Sep; 35(9):1274-86. PubMed ID: 21836485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
    Naito T; Nosho K; Ito M; Igarashi H; Mitsuhashi K; Yoshii S; Aoki H; Nomura M; Sukawa Y; Yamamoto E; Adachi Y; Takahashi H; Hosokawa M; Fujita M; Takenouchi T; Maruyama R; Suzuki H; Baba Y; Imai K; Yamamoto H; Ogino S; Shinomura Y
    World J Gastroenterol; 2014 Aug; 20(29):10050-61. PubMed ID: 25110432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of secondary malignancy (including breast) in patients with mismatch-repair protein deficiency.
    Clay MR; Allison KH; Folkins AK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1494-500. PubMed ID: 24921635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characterization of "sessile serrated" adenoma to carcinoma transition in six early colorectal cancers.
    Cappellesso R; Lo Mele M; Munari G; Rosa-Rizzotto E; Guido E; De Lazzari F; Pilati P; Tonello M; Farinati F; Realdon S; Fassan M; Rugge M
    Pathol Res Pract; 2019 May; 215(5):957-962. PubMed ID: 30738693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
    J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
    Nagasaka T; Sasamoto H; Notohara K; Cullings HM; Takeda M; Kimura K; Kambara T; MacPhee DG; Young J; Leggett BA; Jass JR; Tanaka N; Matsubara N
    J Clin Oncol; 2004 Nov; 22(22):4584-94. PubMed ID: 15542810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
    Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
    APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
    Venderbosch S; Nagtegaal ID; Maughan TS; Smith CG; Cheadle JP; Fisher D; Kaplan R; Quirke P; Seymour MT; Richman SD; Meijer GA; Ylstra B; Heideman DA; de Haan AF; Punt CJ; Koopman M
    Clin Cancer Res; 2014 Oct; 20(20):5322-30. PubMed ID: 25139339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma.
    Bettington M; Walker N; Rosty C; Brown I; Clouston A; McKeone D; Pearson SA; Leggett B; Whitehall V
    Gut; 2017 Jan; 66(1):97-106. PubMed ID: 26475632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MLH1, BRAF and p53 - searching for significant markers to predict evolution towards adenocarcinoma in colonic sessile serrated lesions.
    Răduţă D; Dincă OM; Micu GV; Nichita L; Cioplea MD; Buşcă RM; Ardeleanu R; Mateescu RB; Benguş A; Zurac SA; Popp CG; Vlădan GC
    Rom J Morphol Embryol; 2021; 62(4):971-979. PubMed ID: 35673816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
    Vos JR; Fakkert IE; Spruijt L; Willems RW; Langenveld S; Mensenkamp AR; Leter EM; Nagtegaal ID; Ligtenberg MJL; Hoogerbrugge N;
    Int J Cancer; 2020 Oct; 147(8):2150-2158. PubMed ID: 32510614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).
    Newton K; Jorgensen NM; Wallace AJ; Buchanan DD; Lalloo F; McMahon RF; Hill J; Evans DG
    J Med Genet; 2014 Dec; 51(12):789-96. PubMed ID: 25280751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
    Lubomierski N; Plotz G; Wormek M; Engels K; Kriener S; Trojan J; Jungling B; Zeuzem S; Raedle J
    Cancer; 2005 Sep; 104(5):952-61. PubMed ID: 16015629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sporadic deficient mismatch repair in colorectal cancer increases the risk for non-colorectal malignancy: A European multicenter cohort study.
    Gkekas I; Jan N; Kaprio T; Beilmann-Lehtonen I; Fabian P; Tavelin B; Böckelman C; Edin S; Strigård K; Svoboda T; Hagström J; Barsova L; Jirasek T; Haglund C; Palmqvist R; Gunnarsson U
    J Surg Oncol; 2024 Jun; 129(7):1295-1304. PubMed ID: 38470492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma.
    Kimura T; Yamamoto E; Yamano HO; Suzuki H; Kamimae S; Nojima M; Sawada T; Ashida M; Yoshikawa K; Takagi R; Kato R; Harada T; Suzuki R; Maruyama R; Kai M; Imai K; Shinomura Y; Sugai T; Toyota M
    Am J Gastroenterol; 2012 Mar; 107(3):460-9. PubMed ID: 22233696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.